Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Repligen's pe ratio was 234.5× on Nov 11, 2026, against 889.8× a year earlier. Over the last 5 years it ranged from 45.3× to 889.8×, with a median of 136.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 234.5× | −557.1 |
| 2024 | Oct 31, 2024 | 791.6× | +692.1 |
| 2023 | Dec 29, 2023 | 99.5× | +43.0 |
| 2022 | Dec 30, 2022 | 56.5× | −69.6 |
| 2021 | Dec 31, 2021 | 126.1× | −107.6 |
| 2020 | Dec 31, 2020 | 233.7× | +44.9 |
| 2019 | Dec 31, 2019 | 188.8× | +85.4 |
| 2018 | Dec 31, 2018 | 103.4× | +41.9 |
| 2017 | Dec 29, 2017 | 61.5× | −92.6 |
| 2016 | Dec 30, 2016 | 154.1× | +49.3 |
| 2015 | Dec 31, 2015 | 104.8× | +49.8 |
| 2014 | Dec 31, 2014 | 55.0× | – |
See a number that looks wrong?